Literature DB >> 4830223

Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia.

J A Charlesworth, D G Williams, E Sherington, P J Lachmann, D K Peters.   

Abstract

Metabolic studies using radioiodine-labeled third component of complement (C3) and the glycine-rich beta glycoprotein (GBG), a major component of the C3b-feedback pathway, were undertaken in normal subjects, in 22 patients with evidence of complement activation, and in 11 patients with various renal diseases without evidence of complement activation. In seven normal subjects GBG was found to be a rapidly metabolized protein with catabolic rates ranging from 1.7% to 2.2% of the plasma pool/h, synthesis rates from 0.14 to 0.21 mg/kg per h. and extravascular/intravascular distribution ratios from 0.81 to 1.31. In patients with reduced plasma C3, both increased C3 fractional catabolic rates and reduced C3 synthesis rates were observed, and in some patients there was evidence of increased extravascular distribution of the protein. GBG catabolism was usually increased when there was evidence of C3 activation, presumably reflecting activation of the C3b-feedback; but GBG turnover was normal or only slightly accelerated in some patients with accelerated C3 catabolism and profound hypocomplementemia, suggesting that reduced C3 synthesis had limited activation of the C3b-feedback.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4830223      PMCID: PMC302653          DOI: 10.1172/JCI107708

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  27 in total

1.  Distribution and metabolism of I131 labeled proteins in man.

Authors:  S A BERSON; R S YALOW
Journal:  Fed Proc       Date:  1957-07

2.  The theory of tracer experiments with 131I-labelled plasma proteins.

Authors:  C M MATTHEWS
Journal:  Phys Med Biol       Date:  1957-07       Impact factor: 3.609

3.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

4.  Hypocomplementemia with cutaneous vasculitis and arthritis. Possible immune complex syndrome.

Authors:  F C McDuffie; W M Sams; J E Maldonado; P H Andreini; D L Conn; E A Samayoa
Journal:  Mayo Clin Proc       Date:  1973-05       Impact factor: 7.616

5.  Serum C'3 lytic system in patients with glomerulonephritis.

Authors:  R E Spitzer; E H Vallota; J Forristal; E Sudora; A Stitzel; N C Davis; C D West
Journal:  Science       Date:  1969-04-25       Impact factor: 47.728

6.  Metabolism of the third component of complement (C3) in normal human subjects.

Authors:  J A Charlesworth; D G Williams; E Sherington; D K Peters
Journal:  Clin Sci Mol Med       Date:  1974-02

7.  The alternate pathway of complement activation. The role of C3 and its inactivator (KAF).

Authors:  P A Nicol; P J Lachmann
Journal:  Immunology       Date:  1973-02       Impact factor: 7.397

8.  Isolation and properties of a glycine-rich beta-glycoprotein of human serum.

Authors:  T Boenisch; C A Alper
Journal:  Biochim Biophys Acta       Date:  1970-12-22

9.  Complement studies in membrano-proliferative glomerulonephritis.

Authors:  D K Peters; A Martin; A Weinstein; J S Cameron; T M Barratt; C S Ogg; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1972-07       Impact factor: 4.330

10.  Properdin anc C3 proactivator: alternate pathway components in human glomerulonephritis.

Authors:  R H McLean; A F Michael
Journal:  J Clin Invest       Date:  1973-03       Impact factor: 14.808

View more
  53 in total

1.  Identification of nephritic factor as an immunoglobulin.

Authors:  D G Williams; A Bartlett; P Duffus
Journal:  Clin Exp Immunol       Date:  1978-09       Impact factor: 4.330

Review 2.  Review: assessment of complement activation in clinical immunology laboratories: time for reappraisal?

Authors:  M Peakman; G Senaldi; D Vergani
Journal:  J Clin Pathol       Date:  1989-10       Impact factor: 3.411

3.  Complement activation profiles in disease.

Authors:  D L Brown
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1979

4.  A quantitative lateral flow assay to detect complement activation in blood.

Authors:  Elizabeth C Schramm; Nick R Staten; Zhouning Zhang; Samuel S Bruce; Christopher Kellner; John P Atkinson; Vasileios C Kyttaris; George C Tsokos; Michelle Petri; E Sander Connolly; Paul K Olson
Journal:  Anal Biochem       Date:  2015-02-04       Impact factor: 3.365

5.  Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.

Authors:  L H Perrin; P H Lambert; P A Miescher
Journal:  J Clin Invest       Date:  1975-07       Impact factor: 14.808

6.  Cutaneous leishmaniasis: immune complex formation and necrosis in the acute phase.

Authors:  M J Ridley; D S Ridley
Journal:  Br J Exp Pathol       Date:  1984-06

7.  Human fibronectin metabolism.

Authors:  B A Pussell; P W Peake; M A Brown; J A Charlesworth
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

8.  Activation of the alternative complement pathway in systemic lupus erythematosus.

Authors:  M R Wilson; C M Arroyave; R M Nakamura; J H Vaughan; E M Tan
Journal:  Clin Exp Immunol       Date:  1976-10       Impact factor: 4.330

9.  Complement activating cryoglobulins in the nephritis of systemic lupus erythematosus.

Authors:  D Adu; D G Williams
Journal:  Clin Exp Immunol       Date:  1984-03       Impact factor: 4.330

10.  C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.

Authors:  K Whaley; P H Schur; S Ruddy
Journal:  J Clin Invest       Date:  1976-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.